or
Remember me
Back
Everything relies on the results of the Field Tests. If they can replicate the data in a real world setting, then the FDA will fast track this submission and it will hit $100/share in no time. If not, this company drops to pennies!
Receive investor kits and email updates from Stockhouse and directly from these companies.
At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!